Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Literature
1.
Tingen HSA, Tubben A, Bijzet J, et al. Cardiac [(99m)tc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker? Eur J Nucl Med Mol Imaging. 2023;51:681–90.CrossRefPubMedPubMedCentral
2.
Yu A, Chen Y, Tsai C, et al. Tafamidis Treatment decreases 99mTc-Pyrophosphate uptake in patients with Hereditary Ala97Ser Transthyretin amyloid cardiomyopathy. J Am Coll Cardiol Img. 2023;16(6):866–7.CrossRef
Metadata
Title
Letter to the editor concerning “Cardiac [99mTc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker?”
Authors
An-Li Yu
Cheng-Hsuan Tsai
Mei-Fang Cheng
Yen-Hung Lin
Publication date
24-04-2024
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-024-06724-8